Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash Flows From Operating Activities:
Net loss	$ (23,739,000)	$ (25,653,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	654,000	671,000
In-process research and development impairment	0	1,325,000
Goodwill impairment		5,594,000
Change in fair value of contingent consideration	9,031,000	699,000
Loss on asset disposal	1,000
Non - cash lease expense	522,000	452,000
Depreciation	108,000	137,000
Deferred research and development tax credit	(188,000)	(888,000)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	456,000	912,000
Deposits and other assets		1,000
Accounts payable	69,000	123,000
Accrued expenses	(2,277,000)	522,000
Accrued employee benefits	(744,000)	(350,000)
Operating lease liability	(562,000)	(482,000)
Net Cash Used In Operating Activities	(16,669,000)	(16,937,000)
Cash Flows From Investing Activities:
Purchases of property and equipment	(35,000)	(1,000)
Net Cash Used In Investing Activities	(35,000)	(1,000)
Cash Flows From Financing Activities:
Payment of loans payable	(70,000)	(67,000)
Proceeds from issuance under at - the - market offering, net of issuance cost	6,833,000	3,603,000
Payment of contingent consideration	(1,000,000)
Proceeds from issuance Common Stock and Warrants offering, net of issuance costs	6,690,000	1,960,000
Proceeds from warrant inducement	3,942,000
Proceeds from long term debt	1,507,000
Proceeds from issuance of common stock for warrant exercises	4,000
Tax credit receivable	287,000
Net Cash Provided By Financing Activities	18,193,000	5,496,000
Effects of exchange rate changes on cash and cash equivalents	(92,000)	(132,000)
Net increase (decrease) in cash and cash equivalents and restricted cash	1,397,000	(11,574,000)
Cash and cash equivalents and restricted at the beginning of this period	11,705,000	23,279,000
Cash and cash equivalents and restricted cash at the end of this period	13,102,000	11,705,000
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet
Cash and cash equivalents	13,056,000	11,609,000
Restricted cash included in other long-term assets	46,000	96,000
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	13,102,000	$ 11,705,000
NONCASH FINANCING ACTIVITIES:
Noncash equity issuance costs and deemed dividend	$ 5,880,000